The current development progress of BRIM’s pipeline is as follows :
PDSP has been proven effective in animal models for indications such as corneal damage, degenerative arthritis, wound healing (such as burns, diabetic foot ulcer, muscle and ligament healing), and alopecia.
Building upon the data, BRIM developed 3 assets, BRM421, BRM424, and BRM521, based on PDSP technology. New indications are under continuous development.
Meanwhile, BRIM is also scouting new technologies to enrich the pipeline further.
